证券代码：600664 证券简称：哈药股份 编号：临 2024-018 哈药集团股份有限公司 关于 2021 年股票期权与限制性股票激励计划首次授予部分第三 个行权期行权条件及第三个解除限售期解除限售条件未成就暨 注销股票期权和回购注销限制性股票的公告 本公司董事会及全体董事保证公告内容不存在任何虚假记载、误导性陈述或者重大遗 漏，并对其内容的真实性、准确性和完整性承担法律责任。 重要内容提示： 本次注销股票期权数量合计 409.35 万份；回购注销限制性股票数量合计 203.16 万股。 限制性股票的回购价格：因公司业绩未达标而回购的价格为授予价格与 中国人民银行定期存款一年期基准利率之和；因担任公司第十届监事会职工监事 不符合有关激励对象规定而回购的价格为授予价格与中国人民银行定期存款一 年期基准利率之和；因离职原因不符合有关激励对象规定而回购的价格为授予价 格。 哈药集团股份有限公司（以下简称"公司"）于 2024 年 4 月 25 日召开第十 届董事会第三次会议，审议通过了《关于 2021 年股票期权与限制性股票激励计 划首次授予部分第三个行权期行权条件及第三个解除限售期解除限售条件未成 就暨注销股票 ...

证券代码：600664 证券简称：哈药股份 编号：临 2024-020 哈药集团股份有限公司 关于 2021 年股票期权与限制性股票激励计划剩余预留授予部分 第二个行权期行权条件及第二个解除限售期解除限售条件未成 就暨注销股票期权和回购注销限制性股票的公告 本公司董事会及全体董事保证公告内容不存在任何虚假记载、误导性陈述或者重大遗 漏，并对其内容的真实性、准确性和完整性承担法律责任。 重要内容提示： 本次注销股票期权数量合计 70.5 万份；回购注销限制性股票数量合计 44.5 万股。 限制性股票的回购价格：因公司业绩未达标而回购的价格为授予价格与 中国人民银行定期存款一年期基准利率之和；因离职原因不符合有关激励对象规 定而回购的价格为授予价格。 哈药集团股份有限公司（以下简称"公司"）于 2024 年 4 月 25 日召开第十 届董事会第三次会议，审议通过了《关于 2021 年股票期权与限制性股票激励计 划首次授予部分第三个行权期行权条件及第三个解除限售期解除限售条件未成 就暨注销股票期权和回购注销限制性股票的议案》《关于 2021 年股票期权与限 制性股票激励计划第一次预留授予部分第三个行权期行权条件及第 ...

十届三次董事会决议公告 哈药集团股份有限公司 证券代码：600664 证券简称：哈药股份 编号：临 2024-016 一、2024 年第一季度报告（同意 9 票，反对 0 票，弃权 0 票） 具体内容详见公司同日在上海证券交易所网站（www.sse.com.cn）披 露的 2024 年第一季度报告。 本议案已经董事会审计委员会 2024 年第三次会议审议通过。 本公司董事会及全体董事保证公告内容不存在任何虚假记载、误导性陈述或者重大遗 漏，并对其内容的真实性、准确性和完整性承担法律责任。 哈药集团股份有限公司（以下简称"公司"）第十届董事会第三次会 议以书面方式发出通知，于 2024 年 4 月 25 日以通讯表决方式召开。会议 应参加董事 9 人，实际参加董事 9 人，会议召开符合《中华人民共和国公 司法》和《公司章程》的有关规定，会议审议通过了如下议案： 二、《关于 2021 年股票期权与限制性股票激励计划首次授予部分第 三个行权期行权条件及第三个解除限售期解除限售条件未成就暨注销股 票期权和回购注销限制性股票的议案》（同意 9 票，反对 0 票，弃权 0 票） 鉴于公司 2021 年股票期权与限制性股票 ...

哈药集团股份有限公司 关于回购注销部分限制性股票通知债权人的公告 本公司董事会及全体董事保证公告内容不存在任何虚假记载、误导性陈述或者重大遗 漏，并对其内容的真实性、准确性和完整性承担法律责任。 证券代码：600664 证券简称：哈药股份 编号：临 2024-022 上述回购注销部分限制性股票将导致注册资本减少，根据《中华人民共和国 公司法》（以下简称"《公司法》"）等相关法律法规的规定，公司特此通知债权人， 债权人自本公告之日起四十五日内，有权要求本公司清偿债务或者提供相应的担 保。债权人未在规定期限内行使上述权利的，本次回购注销将按法定程序继续实 施。公司各债权人如要求本公司清偿债务或提供相应担保的，应根据《公司法》 等法律法规的有关规定向本公司提出书面要求，并随附有关证明文件。 一、债权申报所需材料 公司债权人可持证明债权债务关系存在的合同、协议及其他凭证的原件及复 印件到公司申报债权。 债权人为法人的，需同时携带法人营业执照副本原件及复印件、法定代表人 身份证明文件；委托他人申报的，除上述文件外，还需携带法定代表人授权委托 书和代理人有效身份证的原件及复印件。 债权人为自然人的，需同时携带有效身份证的 ...

Financial Performance - The company's operating revenue for Q1 2024 was CNY 4,142,160,958.07, representing a year-on-year increase of 5.36%[4] - The net profit attributable to shareholders was CNY 176,741,385.26, reflecting a significant increase of 44.52% compared to the same period last year[4] - The net profit attributable to shareholders after deducting non-recurring gains and losses was CNY 159,290,806.61, up by 43.11% year-on-year[4] - Basic earnings per share increased by 40.00% to CNY 0.07 per share[4] - Total operating revenue for Q1 2024 reached ¥4,142,160,958.07, an increase of 5.35% compared to ¥3,931,549,972.98 in Q1 2023[17] - Net profit for Q1 2024 was ¥190,306,825.92, representing a 36.00% increase from ¥139,987,574.96 in Q1 2023[19] - The net profit attributable to shareholders of the parent company for Q1 2024 was ¥176,741,385.26, compared to ¥122,293,236.02 in Q1 2023, marking a growth of 44.41%[19] - Basic and diluted earnings per share for Q1 2024 were both ¥0.07, up from ¥0.05 in Q1 2023[19] Assets and Liabilities - The company's total assets at the end of the reporting period were CNY 14,146,783,796.73, a slight increase of 0.25% from the end of the previous year[5] - The equity attributable to shareholders increased by 3.74% to CNY 4,900,837,590.76 compared to the end of the previous year[5] - As of March 31, 2024, the company's total assets amounted to RMB 14,146,783,796.73, an increase from RMB 14,112,148,916.32 as of December 31, 2023, reflecting a growth of approximately 0.24%[12] - The company's current assets totaled RMB 10,484,467,557.58, compared to RMB 10,396,022,101.31 at the end of 2023, indicating an increase of about 0.84%[12] - Total liabilities as of Q1 2024 amounted to ¥8,533,630,990.83, down from ¥8,689,309,461.28 in the previous year[18] - The total liabilities of the company were RMB 11,000,933,879.06, compared to RMB 11,005,962,440.00 at the end of 2023, showing a marginal decrease of about 0.05%[13] Cash Flow - The net cash flow from operating activities was negative at CNY -270,799,005.53, a decrease of 248.28% year-on-year[4] - In Q1 2024, the net cash flow from operating activities was -270,799,005.53, a decrease from 182,625,091.63 in Q1 2023, indicating a significant decline in operational performance[22] - Total cash inflow from operating activities in Q1 2024 was 3,729,185,278.24, down from 4,022,411,651.90 in Q1 2023, reflecting a year-over-year decrease of approximately 7.3%[22] - Cash outflow from operating activities increased to 3,999,984,283.77 in Q1 2024, compared to 3,839,786,560.27 in Q1 2023, representing an increase of about 4.2%[22] - Cash flow from investing activities showed a net outflow of -14,741,375.45 in Q1 2024, slightly worse than -14,342,365.80 in Q1 2023[23] - Cash inflow from financing activities was 590,000,000.00 in Q1 2024, down from 650,807,640.00 in Q1 2023, indicating a decrease of approximately 9.3%[23] - The net cash flow from financing activities improved to 126,267,552.73 in Q1 2024, compared to 62,865,637.35 in Q1 2023, showing a positive trend[23] Expenses and Costs - The company reduced its financial expenses by 61.26%, amounting to a decrease of CNY 5,100,000, due to effective financing strategies[5] - Total operating costs for Q1 2024 were ¥3,915,903,736.03, up from ¥3,749,463,341.18 in Q1 2023, reflecting a growth of 4.43%[18] - Research and development expenses decreased to ¥25,265,801.00 in Q1 2024 from ¥33,061,277.20 in Q1 2023, a reduction of 23.67%[18] - The company paid 192,394,621.99 in taxes in Q1 2024, down from 240,140,104.18 in Q1 2023, reflecting a reduction of approximately 19.9%[22] Shareholder Information - The number of ordinary shareholders at the end of the reporting period was 101,974[8]

北京市天元律师事务所上海分所 关于哈药集团股份有限公司 2021 年股票期权与限制性股票激励计划 注销部分股票期权及回购注销部分限制性股票 相关事宜的 法律意见 北京市天元律师事务所上海分所 北京市天元律师事务所上海分所 关于哈药集团股份有限公司 2021 年股票期权与限制性股票激励计划 注销部分股票期权及回购注销部分限制性股票相关事宜的 法律意见 京天股字（2023）第 025-5 号 致：哈药集团股份有限公司 北京市天元律师事务所上海分所（以下简称"本所"）接受哈药集团股份有 限公司（以下简称"公司"）的委托，担任公司 2021 年股票期权与限制性股票 激励计划（以下简称"本次激励计划"）的专项中国法律顾问，为公司本次激励 计划注销部分股票期权及回购注销部分限制性股票相关事宜（以下简称"本次注 销"）出具法律意见。 本所及经办律师依据《中华人民共和国公司法》（以下简称"《公司法》"）、 《中华人民共和国证券法》（以下简称"《证券法》"）、《上市公司股权激励 管理办法》（以下简称"《管理办法》"）、《律师事务所从事证券法律业务管 理办法》（以下简称"《证券法律业务管理办法》"）、《律师事务所证券法律 业务执 ...

证券代码：600664 证券简称：哈药股份 编号：临 2024-021 哈药集团股份有限公司 关于注销 2021 年股票期权与限制性股票激励计划第一次预留授 予部分第一个行权期已到期未行权的股票期权的公告 本公司董事会及全体董事保证公告内容不存在任何虚假记载、误导性陈述或者重大遗 漏，并对其内容的真实性、准确性和完整性承担法律责任。 哈药集团股份有限公司（以下简称"公司"）于 2024 年 4 月 25 日召开第十 届董事会第三次会议，审议通过了《关于 2021 年股票期权与限制性股票激励计 划首次授予部分第三个行权期行权条件及第三个解除限售期解除限售条件未成 就暨注销股票期权和回购注销限制性股票的议案》《关于 2021 年股票期权与限 制性股票激励计划第一次预留授予部分第三个行权期行权条件及第三个解除限 售期解除限售条件未成就暨注销股票期权和回购注销限制性股票的议案》《关于 2021 年股票期权与限制性股票激励计划剩余预留授予部分第二个行权期行权条 件及第二个解除限售期解除限售条件未成就暨注销股票期权和回购注销限制性 股票的议案》《关于注销 2021 年股票期权与限制性股票激励计划第一次预留授 予部分第一个 ...

证券代码：600664 证券简称：哈药股份 编号：临2024-017 1、公司第一季度报告的编制和审议程序符合法律法规、《公司章程》和 公司内部管理制度的规定； 2、公司第一季度报告的内容符合中国证监会和上海证券交易所的各项规 定，所包含的信息能从各个方面真实地反映公司 2024 年第一季度的经营和财 务状况，不存在任何虚假记载、误导性陈述或者重大遗漏； 3、在本意见提出前，未发现参与第一季度报告编制和审议的人员有违反 保密规定、内幕交易或其他违反法律法规的行为。 二、《关于2021年股票期权与限制性股票激励计划首次授予部分第三 个行权期行权条件及第三个解除限售期解除限售条件未成就暨注销股票 期权和回购注销限制性股票的议案》（同意 2 票，反对 0 票，弃权 0 票，关 联监事邱芳菊女士已对该议案回避表决） 经核查，公司监事会认为：鉴于公司 2021 年股票期权与限制性股票激 励计划首次授予部分第三个行权期及第三个解除限售期公司业绩未满足 哈药集团股份有限公司 十届三次监事会决议公告 本公司监事会及全体监事保证公告内容不存在任何虚假记载、误导性陈述或者重大遗 漏，并对其内容的真实性、准确性和完整性承担法律责任 ...

Financial Performance - In 2023, Harbin Pharmaceutical Group achieved a revenue of CNY 15,456,578,104.40, representing an increase of 11.93% compared to CNY 13,808,761,327.75 in 2022[22]. - The net profit attributable to shareholders of the listed company for 2023 was CNY 395,263,436.89, a decrease of 15.02% from CNY 465,150,300.61 in 2022[22]. - The net profit after deducting non-recurring gains and losses was CNY 325,313,962.85, which is an increase of 40.50% compared to CNY 231,542,538.65 in 2022[22]. - The net cash flow from operating activities for 2023 was CNY 949,670,974.17, up 52.66% from CNY 622,093,201.43 in 2022[22]. - The company achieved operating revenue of 15.457 billion RMB, a year-on-year increase of 11.93%[31]. - Basic earnings per share decreased by 15.79% to 0.16 RMB, while diluted earnings per share decreased by 11.11% to 0.16 RMB[23]. - The weighted average return on equity decreased by 2.63 percentage points to 8.73%[23]. - The company reported a total sales expense of 231,153.06 million RMB, which is 14.95% of its operating revenue[121]. Assets and Liabilities - As of the end of 2023, the total assets of the company were CNY 14,112,148,916.32, reflecting a growth of 5.04% from CNY 13,434,852,019.63 at the end of 2022[22]. - The net assets attributable to shareholders of the listed company increased to CNY 4,724,089,680.56, a rise of 9.16% from CNY 4,327,758,072.66 in 2022[22]. - The company’s total assets at the end of the period were 14,155.56 million RMB, with accounts receivable decreasing by 62.33% compared to the previous period[84]. - The company’s overseas assets amounted to 359.46 million RMB, representing 2.55% of total assets[86]. Market Strategy and Development - The company plans to continue focusing on research and development of new products and technologies to enhance market competitiveness[6]. - Harbin Pharmaceutical Group is committed to expanding its market presence and exploring potential mergers and acquisitions to drive growth[6]. - The company is actively pursuing market expansion strategies, including entering new geographic regions and increasing distribution channels[99]. - The company is focusing on online health product business development, responding to the growth in health demand and e-commerce consumer traffic[50]. - The company plans to enhance its core competitiveness by addressing key technical challenges and developing platforms for coating, taste-masking, and controlled-release formulations[131]. Research and Development - The company focuses on developing a competitive product portfolio, particularly in the fields of digestion, respiration, anti-infection, cardiovascular, and oncology treatments, with a strong emphasis on generic drugs[35]. - The company is advancing its research and development efforts, focusing on high-tech products with technical barriers, including innovative drugs and generics[35]. - The company has submitted 45 patent applications in 2023, including 25 invention patents, to enhance its innovation capabilities[54]. - The company is actively pursuing new product registrations and has several projects under CDE review, indicating a robust pipeline for future growth[108]. - The company is conducting research on various new products, including lactulose oral solution and compound sulfamethoxazole tablets, which are in the CDE review stage[107]. Operational Efficiency - The company is actively optimizing its supply chain management and production operations to enhance efficiency and reduce costs through strategic procurement and quality management improvements[36]. - The company has implemented a centralized supply chain system for retail operations, optimizing logistics and reducing operational costs[48]. - The company is focusing on optimizing product structure and enhancing brand strength to drive future growth in the health product sector[58]. - The company has established a comprehensive quality management system and was recognized as one of the first "Sterile Drug Quality Assurance Enterprises" in China[53]. Marketing and Sales - The company emphasized enhancing brand positioning and accelerating brand awakening to capture market share in the health product sector[32]. - Membership marketing efforts have led to a membership base of 2.37 million, with member sales accounting for 74% of total sales[48]. - The company is actively expanding its e-commerce channels and marketing strategies to enhance product visibility and sales performance[67]. - The marketing strategy for 2024 includes optimizing sales channels and enhancing brand positioning to better meet consumer needs[137]. Governance and Compliance - The board of directors has optimized its structure, with independent directors now constituting over one-third of the total board members[146]. - The company has established four specialized committees within the board to enhance decision-making processes[146]. - The company has implemented a compliance committee to oversee compliance management and has revised several internal regulations[148]. - The company has a robust information disclosure system, ensuring timely and accurate communication with shareholders[147]. Future Outlook - The company aims to maintain an average annual growth rate of over 8% in revenue and total profit by 2025, as outlined in the "14th Five-Year" plan for the pharmaceutical industry[128]. - The company anticipates industry policy risks due to ongoing healthcare reforms and will adjust its strategies accordingly[140]. - The company plans to implement a shareholder return plan for 2023-2025, focusing on enhancing shareholder value[151]. - The company aims to achieve a revenue of 16.461 billion yuan in 2024, representing a year-on-year growth of 6.5%[135].

证券代码:600664 证券简称:哈药股份 编号:临 2024-011 哈药集团股份有限公司 （包括但不限于确定相关人员；确定保险公司；确定保险金额、保险 费及其他保险条款；选择及聘任保险经纪公司或其他中介机构；签署 一、投保董监高责任险方案 1、投保人：哈药集团股份有限公司 2、被保险人：公司及全体董事、监事、高级管理人员及其他相 关人员（具体以保险合同为准） 3、赔偿限额：不超过人民币 10000 万元（具体以保险合同为准） 4、保费限额：不超过人民币 80 万元/年（具体以招标审批价格 为准） 5、保险期限：12 个月（后续每年可续保或重新投保） 为提高决策效率，董事会提请公司股东大会授权公司管理层在上 述权限内办理董事、监事及高级管理人员责任保险购买的相关事宜 关于购买董监高责任险的公告 本公司董事会及全体董事保证公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 为完善哈药集团股份有限公司（以下简称"公司"）风险管理体 系，降低公司运营风险，促进公司董事、监事及高级管理人员在其职 责范围内更充分地发挥决策、监督和管理职能，保障公司和投资者的 权益， ...